Literature DB >> 32444886

Current state of image-guided focal therapy for prostate cancer.

Rafael R Tourinho-Barbosa1,2, Bradford J Wood3, Andre Luis Abreu4, Bruno Nahar5, Toshitaka Shin6, Selcuk Guven7, Thomas J Polascik8.   

Abstract

PURPOSE: To review the current evidence regarding protocols and outcomes of image-guided focal therapy (FT) for prostate cancer (PCa).
METHODS: A literature search of the latest published studies assessing primary FT for PCa was carried out in Medline and Cochrane library databases followed by a critical review. FT modalities, follow-up strategies, and oncological and toxicity outcomes were summarized and discussed in this review.
RESULTS: Twenty-four studies with six different sources of energy met the inclusion criteria. A heterogeneity of patient selection, energy sources, treatment templates, and definitions of failure was found among the studies. While a third of patients may be found to have additional cancer burden over 3-5 years following FT, most patients will remain free of a radical procedure. The vast majority of patients maintain urinary continence and good erectile function after FT. Acute urinary retention is the most common complication, whilst severe complications remain rare.
CONCLUSION: An increasing number of prospective studies with longer follow-up have been recently published. Acceptable cancer control and low treatment toxicity after FT have been consistently reported. Follow-up imaging and routine biopsy must be encouraged post-FT. While there is no reliable PSA threshold to predict failure after FT, reporting post-FT positive biopsies and retreatment rates appear to be standard when assessing treatment efficacy.

Entities:  

Keywords:  Ablation techniques; Focal therapy; Localized; Outcome; Prostate cancer

Year:  2020        PMID: 32444886     DOI: 10.1007/s00345-020-03254-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  44 in total

1.  Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients.

Authors:  Thomas J Polascik; Vladimir Mouraviev
Journal:  Urology       Date:  2009-08-05       Impact factor: 2.649

Review 2.  Surveillance after prostate focal therapy.

Authors:  Kae Jack Tay; Mahul B Amin; Sangeet Ghai; Rafael E Jimenez; James G Kench; Laurence Klotz; Rodolfo Montironi; Satoru Muto; Ardeshir R Rastinehad; Baris Turkbey; Arnauld Villers; Thomas J Polascik
Journal:  World J Urol       Date:  2018-06-09       Impact factor: 4.226

3.  Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.

Authors:  Mark Douglas Tyson; Tatsuki Koyama; Dan Lee; Karen E Hoffman; Matthew J Resnick; Xiao-Cheng Wu; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Lisa E Paddock; Antoinette Stroup; Vivien Chen; Ralph Conwill; Dan McCollum; David F Penson; Daniel A Barocas
Journal:  Eur Urol       Date:  2018-02-28       Impact factor: 20.096

4.  Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients.

Authors:  Pascal Rischmann; Albert Gelet; Benjamin Riche; Arnauld Villers; Gilles Pasticier; Pierre Bondil; Jean-Luc Jung; Hubert Bugel; Jacques Petit; Harry Toledano; Stéphane Mallick; Olivier Rouvière; Muriel Rabilloud; Hélène Tonoli-Catez; Sebastien Crouzet
Journal:  Eur Urol       Date:  2016-10-06       Impact factor: 20.096

5.  Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.

Authors:  John F Ward; Hiroyuki Nakanishi; Louis Pisters; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-02-10       Impact factor: 5.588

6.  Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.

Authors:  Eduard Baco; Osamu Ukimura; Erik Rud; Ljiljana Vlatkovic; Aud Svindland; Manju Aron; Suzanne Palmer; Toru Matsugasumi; Arnaud Marien; Jean-Christophe Bernhard; John C Rewcastle; Heidi B Eggesbø; Inderbir S Gill
Journal:  Eur Urol       Date:  2014-09-17       Impact factor: 20.096

Review 7.  Ablation energies for focal treatment of prostate cancer.

Authors:  Olivia Lodeizen; Martijn de Bruin; Scott Eggener; Sébastien Crouzet; Sangeet Ghai; Ioannis Varkarakis; Aaron Katz; Jose Luis Dominguez-Escrig; Sascha Pahernik; Theo de Reijke; Jean de la Rosette
Journal:  World J Urol       Date:  2018-06-25       Impact factor: 4.226

Review 8.  New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Authors:  Massimo Valerio; Yannick Cerantola; Scott E Eggener; Herbert Lepor; Thomas J Polascik; Arnauld Villers; Mark Emberton
Journal:  Eur Urol       Date:  2016-08-29       Impact factor: 20.096

Review 9.  Focal or subtotal therapy for early stage prostate cancer.

Authors:  J Stephen Jones
Journal:  Curr Treat Options Oncol       Date:  2007-06

10.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.

Authors:  Stephanie Guillaumier; Max Peters; Manit Arya; Naveed Afzal; Susan Charman; Tim Dudderidge; Feargus Hosking-Jervis; Richard G Hindley; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Ogden; Raj Persad; Karishma Shah; Jan van der Meulen; Jaspal Virdi; Mathias Winkler; Mark Emberton; Hashim U Ahmed
Journal:  Eur Urol       Date:  2018-06-28       Impact factor: 20.096

View more
  2 in total

1.  Imaging and technologies for prostate cancer. Where are we now-where do we go?

Authors:  Jean J M C H de la Rosette; Rafael Sanchez Salas; Art Rastinehad; Thomas J Polascik
Journal:  World J Urol       Date:  2021-03-02       Impact factor: 4.226

Review 2.  Ablative options for prostate cancer management.

Authors:  Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas
Journal:  Turk J Urol       Date:  2020-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.